Presentation is loading. Please wait.

Presentation is loading. Please wait.

David Marash-Whitman 11/20/13. KPC (Klebsiella pneumoniae carbapenemase) 18 infected patients 6 fatalities complete drug resistance persistent presence.

Similar presentations


Presentation on theme: "David Marash-Whitman 11/20/13. KPC (Klebsiella pneumoniae carbapenemase) 18 infected patients 6 fatalities complete drug resistance persistent presence."— Presentation transcript:

1 David Marash-Whitman 11/20/13

2

3 KPC (Klebsiella pneumoniae carbapenemase) 18 infected patients 6 fatalities complete drug resistance persistent presence at NIH center

4 THE PROBLEM increased usage leads to decreased future effectiveness antibiotics are being used excessively development of new antibiotics is expensive finite source of future antibiotics

5 THE SOLUTION promote conservative use of antibiotics incentive to comply remove barriers to compliance

6 THE SOLUTION bioethical responsibility timelinessaffordability

7 THE SOLUTION bioethical responsibility timelinessaffordability

8 THE SOLUTION bioethical responsibility timelinessaffordability

9 THE SOLUTION promote conservative use of antibiotics increase incentive to comply remove barriers to compliance

10 THE SOLUTION Prove-It SepsisSeptifastSepsitest $50 6 hours 25 species $75 3.5 hours 70 species $125 <1 hour 345 species

11 THE SOLUTION bioethical responsibility timelinessaffordability

12 THE SOLUTION bioethical responsibility timelinessaffordability

13 OUTCOMES accessibility of medical technology reduction of inappropriate antibiotic prescriptions

14

15 SHORT TERMPREVENTIONLONG TERM general health vaccination development of new antibiotics conservative use of antibiotics (in humans) (in animals) development of new antimicrobial therapies


Download ppt "David Marash-Whitman 11/20/13. KPC (Klebsiella pneumoniae carbapenemase) 18 infected patients 6 fatalities complete drug resistance persistent presence."

Similar presentations


Ads by Google